Incyte Reports Positive 54-Week Povorcitinib Data in Hidradenitis Suppurativa at AAD 2026

Incyte Reports Positive 54-Week Povorcitinib Results in Hidradenitis Suppurativa at AAD 2026 Incyte has reported encouraging long-term results from its Phase 3 STOP-HS clinical trial program, highlighting the sustained efficacy and safety of povorcitinib in treating hidradenitis suppurativa (HS). The…










